Navigation Links
LA BioMed's Dr. Richard Casaburi investigates causes of COPD
Date:11/13/2012

LOS ANGELES (Nov. 13, 2012) Chronic obstructive pulmonary disease, or COPD, is a progressive disease of the lungs that affects approximately 24 million people in the United States and is now the third leading cause of death in this country. For those who suffer from severe COPD, shortness of breath and other symptoms can make it difficult to perform simple tasks such as doing light housework, taking a walk, or even getting dressed. For more than two decades, Richard Casaburi, Ph.D., M.D., a senior investigator at Los Angeles Biomedical Research Institute (LA BioMed), has focused his research on developing new therapies for COPD. Over the past five years, Dr. Casaburi has participated in a $37 million multi-center study based at National Jewish Health in Denver that seeks to uncover why, out of approximately 45.3 million adults in the United States who smoke cigarettes, only about 25 percent actually acquire COPD. Funded by the National Heart, Blood and Lung Institute of the National Institutes of Health (NIH), this study has now received a second grant to conduct follow-up studies and to obtain more in-depth results.

The initial five-year study began in 2007 with a goal of determining what factors in an individual's genetic makeup would predispose them to developing COPD. The study recruited 10,500 participants from around the country (760 at LA BioMed) who have a history of smoking. The researchers have been conducting a genome-wide association study of the participants to determine their genetic makeup, examining more than one million genetic characteristics from DNA blood samples. This first phase of the study focused on the genes predicting who will develop COPD and what these genes do. By determining the function of the predicting genes, the goal will be to develop new therapies to treat COPD.

"While there is currently no cure for COPD, it is important to understand what genetic deficiencies people may have that would cause them to contract this disease," said Dr. Casaburi. "In doing so, this may lead to the discovery of new therapies that could help successfully treat COPD based on these findings."

Beginning in March 2013, all subjects will be asked to return and participate in the second phase of this study, which will focus on the genetic determinants of COPD progression.

An ancillary study is also being proposed that will highlight LA BioMed's expertise in therapies for exercise intolerance in COPD, a major cause of poor quality of life in these patients. The goal of the study is to determine which genes cause muscle dysfunction in individuals who suffer from this disease. This will tie in with a recent study conducted by Harry Rossiter, Ph.D., a member of Dr. Casaburi's group. By having all of the returning COPD Gene subjects perform a brief, but high-technology test of the muscles of the leg, subjects whose muscles function poorly can be identified. Further analysis will attempt to identify which genes are responsible for poor muscle function.

Drs. Casaburi, Rossiter, and the staff of the Rehabilitation Clinical Trials Center have recently moved into their new "home" in LA BioMed's new Chronic Diseases Clinical Research Center (CDCRC), which was dedicated in October 2012. The new CDCRC is a two-story, 23,171-square-foot research facility that will house the collaborative research efforts of investigator groups studying chronic diseases. In addition to COPD Rehabilitative Medicine, the CDCRC will also house research programs in Atherosclerosis Research and HIV/AIDS, as well as LA BioMed's Investigational Drugs Pharmacy.


'/>"/>

Contact: Diana Soltesz
diana@dsmmedia.com
818-592-6747
Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (LA BioMed)
Source:Eurekalert

Related medicine news :

1. Author, Speaker Richard London Battles Parkinson’s with an Active Lifestyle and the Desire to Give Back
2. ASH honors David Ginsburg, M.D., and Richard Aster, M.D., with 2012 Henry M. Stratton Medal
3. Moffitt researcher investigates 2-drug synergy to treat drug-resistant chronic myeloid leukemia
4. Study reveals how cancer drug causes diabetic-like state
5. What Causes Hot Flashes, Anyway?
6. No Proof That Gum Disease Causes Heart Disease, Experts Say
7. A new Achilles heel in fungus that causes dandruff
8. Cone beam CT proves better for visualizing some causes of hearing loss at half the radiation dose
9. Infection Causes 1 in 6 Cancers Worldwide: Study
10. Pneumonia and preterm birth complications are the leading causes of childhood death
11. Scientists discover gene which causes rare disease in babies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/26/2017)... , ... July 26, 2017 , ... Team Type 1 ... to medicine for everyone affected by diabetes, is excited to announce the 106 college ... Ambassador Program. , Established in 2005, the Team Type 1 Foundation has bestowed ...
(Date:7/26/2017)... (PRWEB) , ... July 26, 2017 , ... ... dogs and cats has opened in Jupiter. The state of the art ... and class leading treatments with a goal of providing heart patients longer lives. ...
(Date:7/26/2017)... ... 2017 , ... Isodiol International Inc. (CSE: ISOL) (OTC: LAGBF) ... development of pharmaceutical and consumer products, announces the operational numbers of its wholly-owned ... International LLC recorded unaudited fiscal Q1 profits of $897,596 based on revenues of ...
(Date:7/26/2017)... ... 2017 , ... Wendy M. Musielak, a partner at the Andrew Cores Family Law ... Association’s third Vice President earlier this year. She will serve the membership in this capacity ... President, in accordance with the organization’s by-laws. , Musielak joined the Andrew ...
(Date:7/26/2017)... ... July 26, 2017 , ... The number of adults 65 years or ... ways to improve asthma control in the population are not well described. In a ... Practice), an official journal of the American Academy of Allergy, Asthma & Immunology (AAAAI), ...
Breaking Medicine News(10 mins):
(Date:7/27/2017)... EXTON, Pa., July 27, 2017  West Pharmaceutical Services, ... financial results for the second-quarter 2017 and updated financial ... Second-Quarter 2017 Highlights Reported ... 2.5% over the prior-year quarter. Net sales at constant ... 2017 reported-diluted EPS was $0.51, compared to $0.60 in ...
(Date:7/25/2017)... BARCELONA, Spain and CAMBRIDGE, Massachusetts ... SOM Biotech, specializing in repurposing drugs to treat rare nervous ... Therapeutics Inc. to clinically develop and market the drug SOM0226 ... reached, the drug achieved very promising results in a Phase ... A new office in the United ...
(Date:7/21/2017)... RESEARCH TRIANGLE PARK, N.C. , July 21, 2017 ... ) announced today that it will report its second ... Thursday, July 27, 2017. ... July 27, 2017, at 9:00 a.m. Eastern Time.  The ... dialing 1-970-315-0533.  A rebroadcast of the teleconference will be ...
Breaking Medicine Technology: